ArticleJournal of diabetes investigation2025
Longitudinal trends in dementia prevalence among individuals with type 2 diabetes in Taiwan (2009-2022).
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study examined the population-based epidemiological prevalence of early- and late-onset dementia in individuals with type 2 diabetes mellitus (T2DM) compared with the general population in Taiwan from 2009 to 2022.
methodsA 14-year nationwide population-based epidemiology study from 2009 to 2022 in Taiwan using the Taiwan National Health Insurance Research Database was conducted to examine the crude and age-standardized dementia prevalence in individuals aged <65 and ≥65. Multivariable logistic regression was used to assess factors associated with dementia prevalence in the T2DM population.
resultsAmong individuals aged ≥65 with T2DM, age-standardized dementia prevalence increased from 5.83 per 100 in 2009 to 7.11 per 100 in 2022, while the crude prevalence ratio compared to the general population ranged from 1.19 to 1.08. In the 40-64 age group, standardized dementia prevalence ranged from 0.58 to 0.43 per 100, with crude ratios ranging from 1.76 to 1.41. Our study found a higher risk of dementia prevalence among individuals aged 65 years and older, particularly among those with T2DM. Although the overall prevalence of dementia in the 40-64 age group was lower compared to older adults, individuals in this younger group with T2DM exhibited a significantly higher risk of developing dementia. Given these findings, public policy should prioritize early preventive strategies for individuals with T2DM to monitor and mitigate dementia progression in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.